238 related articles for article (PubMed ID: 28361339)
1. Use of Antihypertensive Drugs in Neoplastic Patients.
Rizzoni D; De Ciuceis C; Porteri E; Agabiti-Rosei C; Agabiti-Rosei E
High Blood Press Cardiovasc Prev; 2017 Jun; 24(2):127-132. PubMed ID: 28361339
[TBL] [Abstract][Full Text] [Related]
2. Uncontrolled Hypertension and Oncology: Clinical Tips.
Kalaitzidis RG; Elisaf MS
Curr Vasc Pharmacol; 2017; 16(1):23-29. PubMed ID: 28413967
[TBL] [Abstract][Full Text] [Related]
3. Vascular Cardio-Oncology: Vascular Endothelial Growth Factor inhibitors and hypertension.
Versmissen J; Mirabito Colafella KM; Koolen SLW; Danser AHJ
Cardiovasc Res; 2019 Apr; 115(5):904-914. PubMed ID: 30726882
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors.
Kruzliak P; Novák J; Novák M
Am J Hypertens; 2014 Jan; 27(1):3-13. PubMed ID: 24168915
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy.
Curwen JO; Musgrove HL; Kendrew J; Richmond GH; Ogilvie DJ; Wedge SR
Clin Cancer Res; 2008 May; 14(10):3124-31. PubMed ID: 18483380
[TBL] [Abstract][Full Text] [Related]
6. Management of hypertension in angiogenesis inhibitor-treated patients.
Izzedine H; Ederhy S; Goldwasser F; Soria JC; Milano G; Cohen A; Khayat D; Spano JP
Ann Oncol; 2009 May; 20(5):807-15. PubMed ID: 19150949
[TBL] [Abstract][Full Text] [Related]
7. Anti-VEGF Anticancer Drugs: Mind the Hypertension.
Katsi V; Zerdes I; Manolakou S; Makris T; Nihoyannopoulos P; Tousoulis D; Kallikazaros I
Recent Adv Cardiovasc Drug Discov; 2014; 9(2):63-72. PubMed ID: 26123049
[TBL] [Abstract][Full Text] [Related]
8. Angiogenesis and hypertension: the dual role of anti-hypertensive and anti-angiogenic therapies.
Ferroni P; Della-Morte D; Palmirotta R; Rundek T; Guadagni F; Roselli M
Curr Vasc Pharmacol; 2012 Jul; 10(4):479-93. PubMed ID: 22272903
[TBL] [Abstract][Full Text] [Related]
9. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.
Hamnvik OP; Choueiri TK; Turchin A; McKay RR; Goyal L; Davis M; Kaymakcalan MD; Williams JS
Cancer; 2015 Jan; 121(2):311-9. PubMed ID: 25236375
[TBL] [Abstract][Full Text] [Related]
10. Team-Based Approach to Management of Hypertension Associated with Angiogenesis Inhibitors.
Patel S; Dushenkov A; Jungsuwadee P; Krishnaswami A; Barac A
J Cardiovasc Transl Res; 2020 Jun; 13(3):463-477. PubMed ID: 32430701
[TBL] [Abstract][Full Text] [Related]
11. Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
Launay-Vacher V; Deray G
Anticancer Drugs; 2009 Jan; 20(1):81-2. PubMed ID: 19343005
[TBL] [Abstract][Full Text] [Related]
12. Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome.
Small HY; Montezano AC; Rios FJ; Savoia C; Touyz RM
Can J Cardiol; 2014 May; 30(5):534-43. PubMed ID: 24786444
[TBL] [Abstract][Full Text] [Related]
13. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker.
Robinson ES; Khankin EV; Karumanchi SA; Humphreys BD
Semin Nephrol; 2010 Nov; 30(6):591-601. PubMed ID: 21146124
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1.
Lankhorst S; Kappers MH; van Esch JH; Danser AH; van den Meiracker AH
J Hypertens; 2013 Mar; 31(3):444-54; discussion 454. PubMed ID: 23221987
[TBL] [Abstract][Full Text] [Related]
15. Endothelin-1 and antiangiogenesis.
Lankhorst S; Danser AH; van den Meiracker AH
Am J Physiol Regul Integr Comp Physiol; 2016 Feb; 310(3):R230-4. PubMed ID: 26511523
[TBL] [Abstract][Full Text] [Related]
16. VEGF kinase inhibitors: how do they cause hypertension?
Bhargava P
Am J Physiol Regul Integr Comp Physiol; 2009 Jul; 297(1):R1-5. PubMed ID: 19439616
[TBL] [Abstract][Full Text] [Related]
17. Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs).
Cosmai L; Gallieni M; Liguigli W; Porta C
J Nephrol; 2017 Apr; 30(2):171-180. PubMed ID: 27154025
[TBL] [Abstract][Full Text] [Related]
18. Pre-existing antihypertensive treatment predicts early increase in blood pressure during bevacizumab therapy: the prospective AVALUE cohort study.
Wicki A; Hermann F; Prêtre V; Winterhalder R; Kueng M; von Moos R; Rochlitz C; Herrmann R
Oncol Res Treat; 2014; 37(5):230-6. PubMed ID: 24853781
[TBL] [Abstract][Full Text] [Related]
19. Etiology of angiogenesis inhibition-related hypertension.
Lankhorst S; Saleh L; Danser AJ; van den Meiracker AH
Curr Opin Pharmacol; 2015 Apr; 21():7-13. PubMed ID: 25500206
[TBL] [Abstract][Full Text] [Related]
20. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
Maitland ML; Bakris GL; Black HR; Chen HX; Durand JB; Elliott WJ; Ivy SP; Leier CV; Lindenfeld J; Liu G; Remick SC; Steingart R; Tang WH;
J Natl Cancer Inst; 2010 May; 102(9):596-604. PubMed ID: 20351338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]